ATE417617T1 - Mittel zur steurung der expression von il-12 - Google Patents

Mittel zur steurung der expression von il-12

Info

Publication number
ATE417617T1
ATE417617T1 AT02705197T AT02705197T ATE417617T1 AT E417617 T1 ATE417617 T1 AT E417617T1 AT 02705197 T AT02705197 T AT 02705197T AT 02705197 T AT02705197 T AT 02705197T AT E417617 T1 ATE417617 T1 AT E417617T1
Authority
AT
Austria
Prior art keywords
expression
active ingredient
hyaluronan
interleukin
enhancer
Prior art date
Application number
AT02705197T
Other languages
English (en)
Inventor
Akira Asari
Hitoshi Kurihara
Original Assignee
Seikagaku Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seikagaku Kogyo Co Ltd filed Critical Seikagaku Kogyo Co Ltd
Application granted granted Critical
Publication of ATE417617T1 publication Critical patent/ATE417617T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
AT02705197T 2001-03-15 2002-03-14 Mittel zur steurung der expression von il-12 ATE417617T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001074078 2001-03-15
JP2001074077 2001-03-15

Publications (1)

Publication Number Publication Date
ATE417617T1 true ATE417617T1 (de) 2009-01-15

Family

ID=26611324

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02705197T ATE417617T1 (de) 2001-03-15 2002-03-14 Mittel zur steurung der expression von il-12

Country Status (7)

Country Link
US (1) US20040097465A1 (de)
EP (1) EP1369119B1 (de)
JP (1) JP4234439B2 (de)
AT (1) ATE417617T1 (de)
CA (1) CA2440744C (de)
DE (1) DE60230388D1 (de)
WO (1) WO2002074318A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7871984B2 (en) 2003-04-23 2011-01-18 Yukio Sato Methylated CpG polynucleotide
HUP0303779A2 (en) * 2003-11-20 2006-02-28 Richter Gedeon Vegyeszet Pharmaceutical compositions containing hyaluronan complex for the treatment of sclerosis multiplex
JP4889206B2 (ja) * 2004-07-01 2012-03-07 有限会社 シーバイオン Ｉｌ−１２産生誘導活性を有するマクロファージ活性化剤
JP4528898B2 (ja) * 2004-07-26 2010-08-25 独立行政法人科学技術振興機構 ケモカイン受容体ｃｃｒ１０の発現誘導剤
JP4576583B2 (ja) * 2005-03-22 2010-11-10 キユーピー株式会社 ヒアルロン酸またはその塩、およびその製造方法、ならびにこれを含有する化粧料および食品組成物
US20070099867A1 (en) * 2005-05-24 2007-05-03 Glycoscience Laboratories, Inc. Pharmaceutical agent containing hyaluronan as an active ingredient
JP2009091248A (ja) * 2006-01-17 2009-04-30 Toshitsu Kagaku Kenkyusho:Kk 外傷性神経障害および／または運動機能障害の治療薬
CN101415731B (zh) 2006-02-24 2011-11-02 丘比株式会社 新型低分子透明质酸和/或其盐以及使用其的化妆品、医药组合物和食品组合物
FR2908658B1 (fr) * 2006-11-20 2011-11-11 Centre Nat Rech Scient Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l'il-12
CA2641571C (en) 2006-12-05 2010-01-19 Glycoscience Laboratories, Inc. Treatment of osteoarthritis
JP2008266171A (ja) * 2007-04-18 2008-11-06 Q P Corp 自己免疫疾患緩和剤ならびにこれを含有する医薬品および食品
PT2254869T (pt) 2008-03-07 2017-07-18 Acraf Novos derivados de 1-benzil-3-hidroximetilindazole e suas utilizações no tratamento de doenças com base na expressão de cx3cr1 e p40
CN101965337B (zh) 2008-03-07 2013-11-06 方济各安吉利克化学联合股份有限公司 1-苄基-3-羟基甲基吲唑衍生物及其在治疗基于MCP-1、CX3CR1和p40表达的疾病中的用途
WO2009113512A1 (ja) * 2008-03-11 2009-09-17 キユーピー株式会社 Ｓｏｃｓ３発現促進剤、これを含有する医薬品および食品、ならびにｓｏｃｓ３の発現を促進する方法
JPWO2009113512A1 (ja) * 2008-03-11 2011-07-21 キユーピー株式会社 Ｓｏｃｓ３発現促進剤、これを含有する医薬品および食品、ならびにｓｏｃｓ３の発現を促進する方法
FR2931480B1 (fr) * 2008-05-23 2016-04-01 Centre Nat Rech Scient Analogues synthetiques de phosphatidyl-myo-inositol mannosides pourvus d'une active inhibitrice de la reponse inflammatoire
US8462765B2 (en) * 2008-08-20 2013-06-11 Qualcomm Incorporated Method and apparatus to perform ranging operations for wireless stations
ES2665254T3 (es) 2011-07-12 2018-04-25 Holy Stone Healthcare Co., Ltd. Composiciones que comprenden ácido hialurónico para tratamiento y prevención de enfermedades relacionadas con las mucosas
WO2013125634A1 (ja) * 2012-02-22 2013-08-29 株式会社ヒアルロン酸研究所 ヒアルロン酸フラグメントを有効成分とするサーチュイン誘導剤、組織修復剤、肝細胞増殖因子誘導剤、組織恒常性維持剤、及びｔｌｒ４作用剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5095037B1 (en) * 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
JP4010574B2 (ja) * 1994-12-05 2007-11-21 電気化学工業株式会社 皮膚外用剤
WO1997025051A1 (en) * 1996-01-11 1997-07-17 Hyal Pharmaceutical Corporation Oral administration of effective amounts of forms of hyaluronic acid

Also Published As

Publication number Publication date
JPWO2002074318A1 (ja) 2004-07-08
US20040097465A1 (en) 2004-05-20
EP1369119A4 (de) 2004-12-15
JP4234439B2 (ja) 2009-03-04
WO2002074318A1 (fr) 2002-09-26
DE60230388D1 (de) 2009-01-29
EP1369119B1 (de) 2008-12-17
EP1369119A1 (de) 2003-12-10
CA2440744A1 (en) 2002-09-26
CA2440744C (en) 2009-12-08

Similar Documents

Publication Publication Date Title
ATE417617T1 (de) Mittel zur steurung der expression von il-12
DE60043587D1 (de) Mittel für erkrankungen assoziert mit knochensubstanzverlust
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
WO2003053359A3 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
PT1447399E (pt) Derivado de 2-oxo-1-pirrolidina e as suas utilizacoes farmaceuticas
NO950297D0 (no) Prolinamidderivater
CY1107992T1 (el) Συνθεσεις πολυαμιδο-αμικου οξεος υδατικης βασεως
EP1783126A3 (de) N-Oxide von N-Phenyl-2-Pyrimidinamin Derivaten
EP1734041A3 (de) Platelet adp rezeptor inhibitoren
ATE253351T1 (de) Desodoriende zubereitungen enthaltend wasserlösliche -(1,3)-glucane
ATE363267T1 (de) Mittel zur verbesserung der hauttextur
DE69834500D1 (de) Xanthinderivative zur behandlung von hirnischämie
NO20062857L (no) Farmasoytisk preparat omfattende et sink-hyaluronatkompleks for behandling av multippel sklerose
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
EP1992338A3 (de) Pharmazeutische Zubereitungen zur oralen Verwendung von Heparin und seinen Derivaten
IL131216A0 (en) Drugs inhibiting progress of pterygium and postoperative recurrence of the same
BR9904075A (pt) Cetonas
DK1352658T3 (da) Forebyggelse eller lægemiddel mod endometriose
MXPA05014143A (es) Derivados de cumarina para el tratamiento de trastornos oftalmicos.
HU0102987D0 (en) Pharmaceutical composition for treating parkinson's disease comprising astrocyte function-improving agent as active ingredient
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
ATE243219T1 (de) 9a, 11b-dehydro derivative von 9-oxime-3-keto-6-0-methylerythromycin
SE9902674D0 (sv) New composition

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties